Zinc complex of 3,5-di-tert-butyl salicylate inhibits viability, migration, and invasion in triple-negative breast cancer cells

Sci Rep. 2022 Mar 16;12(1):4545. doi: 10.1038/s41598-022-08704-0.

Abstract

The zinc complex of 3,5-di-tert-butyl salicylate (Zn{[CH3)3C]2Sal}22-) is a zinc ion chelate of salicylate. In this study, we found that this compound inhibits viability, invasion, and migration and induces apoptosis in triple-negative breast cancer 4T1 cells. RNA-seq showed that the expression of 17 genes was upregulated and 26 genes were downregulated significantly by Zn{[CH3)3C]2Sal}22- treatment. Further GO and KEGG analysis showed that the activity of Zn{[CH3)3C]2Sal}22- against triple-negative breast cancer cells may be involved in the JAK-STAT3, HIF-1, and TNF signaling pathways. The expression of key genes was verified by RT-PCR. The phosphorylation of STAT3 and its upstream SRC decreased drastically upon Zn{[CH3)3C]2Sal}22- treatment, as demonstrated by western blot. Our results indicate that Zn{[CH3)3C]2Sal}22- inhibits the activity of TNBC cells by downregulating the STAT3 signaling through the SRC pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cell Movement / physiology
  • Cell Proliferation
  • Humans
  • Salicylates / pharmacology
  • Triple Negative Breast Neoplasms* / drug therapy
  • Triple Negative Breast Neoplasms* / genetics
  • Triple Negative Breast Neoplasms* / metabolism
  • Zinc / pharmacology

Substances

  • Salicylates
  • Zinc
  • butyl salicylate